12:00 AM
 | 
Apr 01, 2013
 |  BC Week In Review  |  Company News  |  Sales & Marketing

Eisai sales and marketing update

Eisai will establish a new sales and marketing operation in Moscow, Russia, and plans to launch breast cancer drug Halaven eribulin as its first product this quarter. The pharma then expects to launch its epilepsy portfolio, which includes...

Read the full 178 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >